MX2020000604A - Métodos terapéuticos y de diagnóstico para el cáncer. - Google Patents
Métodos terapéuticos y de diagnóstico para el cáncer.Info
- Publication number
- MX2020000604A MX2020000604A MX2020000604A MX2020000604A MX2020000604A MX 2020000604 A MX2020000604 A MX 2020000604A MX 2020000604 A MX2020000604 A MX 2020000604A MX 2020000604 A MX2020000604 A MX 2020000604A MX 2020000604 A MX2020000604 A MX 2020000604A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- methods
- individual
- sample
- therapeutic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 8
- 201000011510 cancer Diseases 0.000 title abstract 8
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 7
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 2
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 108700028369 Alleles Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000000869 mutational effect Effects 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 230000000392 somatic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
- G06F16/28—Databases characterised by their database models, e.g. relational or object models
- G06F16/284—Relational databases
- G06F16/285—Clustering or classification
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Databases & Information Systems (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Data Mining & Analysis (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Theoretical Computer Science (AREA)
Abstract
La presente invención proporciona métodos terapéuticos, de diagnóstico y pronóstico para el cáncer. La invención proporciona métodos para tratar un cáncer, métodos para determinar si un individuo que tiene cáncer puede responder a un tratamiento que incluye un inhibidor del punto de control inmunitario (por ejemplo, un antagonista de unión al eje PD-L1), métodos para predecir la capacidad de respuesta de un individuo que tiene un cáncer para un tratamiento que incluye un inhibidor del punto de control inmunitario (p. ej., un antagonista de unión al eje PD-L1), métodos para seleccionar una terapia para un individuo que tiene cáncer, métodos para proporcionar un pronóstico para un individuo que tiene un cáncer y métodos de monitoreo una respuesta de un individuo que tiene un cáncer, basada en una puntuación de carga mutacional de tumor en sangre (bTMB) o una frecuencia máxima de alelos somáticos (MSAF) de una muestra (por ejemplo, una muestra de sangre completa, una muestra de plasma, una muestra de suero o un combinación de los mismos) del individuo.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762535605P | 2017-07-21 | 2017-07-21 | |
US201762553034P | 2017-08-31 | 2017-08-31 | |
US201862652843P | 2018-04-04 | 2018-04-04 | |
US201862680516P | 2018-06-04 | 2018-06-04 | |
PCT/US2018/043074 WO2019018757A1 (en) | 2017-07-21 | 2018-07-20 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020000604A true MX2020000604A (es) | 2020-09-10 |
Family
ID=63104170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020000604A MX2020000604A (es) | 2017-07-21 | 2018-07-20 | Métodos terapéuticos y de diagnóstico para el cáncer. |
Country Status (11)
Country | Link |
---|---|
US (1) | US11674962B2 (es) |
EP (1) | EP3655034A1 (es) |
JP (2) | JP2020527351A (es) |
KR (2) | KR20240006698A (es) |
CN (1) | CN111492245A (es) |
AU (2) | AU2018304458B2 (es) |
CA (1) | CA3069469A1 (es) |
IL (1) | IL271888B1 (es) |
MX (1) | MX2020000604A (es) |
TW (1) | TWI823859B (es) |
WO (1) | WO2019018757A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201702723VA (en) | 2014-10-29 | 2017-05-30 | Five Prime Therapeutics Inc | Combination therapy for cancer |
AU2017205089B2 (en) | 2016-01-08 | 2023-10-05 | F. Hoffmann-La Roche Ag | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
CN109476731A (zh) | 2016-02-29 | 2019-03-15 | 基础医药有限公司 | 治疗癌症的方法 |
JP2020518648A (ja) | 2017-05-08 | 2020-06-25 | グリットストーン オンコロジー インコーポレイテッド | アルファウイルス新生抗原ベクター |
BR112020004879A2 (pt) * | 2017-09-13 | 2020-09-15 | Five Prime Therapeutics, Inc. | métodos para tratar o câncer pancreático, para tratar o câncer e para determinar a responsividade de um sujeito com câncer |
CA3079253A1 (en) | 2017-11-03 | 2019-05-09 | Guardant Health, Inc. | Normalizing tumor mutation burden |
SG11202100344WA (en) | 2018-07-23 | 2021-02-25 | Guardant Health Inc | Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage |
CA3109539A1 (en) | 2018-08-31 | 2020-03-05 | Guardant Health, Inc. | Microsatellite instability detection in cell-free dna |
EP3893932A4 (en) * | 2018-12-12 | 2022-09-07 | Medimmune, LLC | BLOOD-BASED TUMORMUTATION LOAD AS A PREDICTOR OF OVERALL SURVIVAL IN NON-SMALL CELL LUNG CANCER |
WO2020146719A1 (en) * | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Co-assays to functional cancer biomarker assays |
WO2020163589A1 (en) | 2019-02-08 | 2020-08-13 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
BR112021018545A2 (pt) * | 2019-03-18 | 2021-12-14 | Univ Indiana Res & Tech Corp | Método para eliminar ou inibir o crescimento de células cancerosas em um paciente que tem câncer e uso de uma droga bioativável de nqo1 em combinação com um segundo agente |
CA3135844A1 (en) * | 2019-04-02 | 2020-10-08 | Board Of Regents, The University Of Texas System | Combinations of transcription inhibitors and immune checkpoint inhibitors for treatment of disease |
CN110229894B (zh) * | 2019-05-21 | 2020-09-08 | 武汉大学 | 一种基因组合及其在制备预测接受免疫检查点抑制剂治疗患者预后的试剂中的应用 |
CA3140019A1 (en) | 2019-05-30 | 2020-12-03 | Gritstone Bio, Inc. | Modified adenoviruses |
US11396679B2 (en) | 2019-05-31 | 2022-07-26 | Universal Diagnostics, S.L. | Detection of colorectal cancer |
CN110229902A (zh) * | 2019-06-24 | 2019-09-13 | 至本医疗科技(上海)有限公司 | 用于胃癌预后预测的评估基因群的确定方法 |
CN112121169B (zh) * | 2019-06-24 | 2023-10-24 | 广州再极医药科技有限公司 | 用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂 |
WO2021028768A1 (en) * | 2019-08-13 | 2021-02-18 | Inivata Ltd. | METHOD FOR ALTERING THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS BASED ON ANALYSIS OF ctDNA |
JP2022544289A (ja) * | 2019-08-14 | 2022-10-17 | コディアック バイオサイエンシーズ, インコーポレイテッド | Stat6を標的とする細胞外小胞-aso構築物 |
US11898199B2 (en) | 2019-11-11 | 2024-02-13 | Universal Diagnostics, S.A. | Detection of colorectal cancer and/or advanced adenomas |
EP4087940A4 (en) * | 2020-01-10 | 2024-04-10 | Gritstone bio, Inc. | CELLULAR DNA MONITORING |
CN111424084A (zh) * | 2020-03-16 | 2020-07-17 | 南京世和基因生物技术股份有限公司 | 一种bTMB标记物、检测试剂盒以及用途 |
WO2021222167A1 (en) * | 2020-04-28 | 2021-11-04 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
EP4150122A1 (en) * | 2020-05-12 | 2023-03-22 | Astrazeneca AB | Biomarkers for predicting overall survival in recurrent/metastatic head and neck squamous cell carcinoma |
WO2021230687A1 (ko) * | 2020-05-13 | 2021-11-18 | 주식회사 루닛 | 의학 데이터로부터 바이오마커와 관련된 의학적 예측을 생성하는 방법 및 시스템 |
US11530453B2 (en) * | 2020-06-30 | 2022-12-20 | Universal Diagnostics, S.L. | Systems and methods for detection of multiple cancer types |
WO2022032196A2 (en) | 2020-08-06 | 2022-02-10 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
US20230287126A1 (en) * | 2020-08-07 | 2023-09-14 | Bio-Thera Solutions, Ltd. | Anti-pd-l1 antibody and use thereof |
CN112530581B (zh) * | 2020-12-03 | 2023-11-21 | 安徽医科大学第一附属医院 | 一种前列腺癌患者的免疫分子分类系统及其应用 |
WO2022194255A1 (en) * | 2021-03-19 | 2022-09-22 | Shanghai Junshi Biosciences Co., Ltd. | Method of treating urothelial carcinoma |
WO2023086951A1 (en) * | 2021-11-12 | 2023-05-19 | Foundation Medicine, Inc. | Circulating tumor dna fraction and uses thereof |
CN114736967B (zh) * | 2022-05-07 | 2024-06-11 | 北京大学肿瘤医院 | 预测免疫检查点抑制剂疗法原发耐药的标志物及方法 |
WO2023220156A1 (en) * | 2022-05-10 | 2023-11-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Novel use of ctdna to identify locally advanced and metastatic upper tract urothelial carcinoma |
US20240003888A1 (en) | 2022-05-17 | 2024-01-04 | Guardant Health, Inc. | Methods for identifying druggable targets and treating cancer |
WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
WO2024097998A1 (en) * | 2022-11-04 | 2024-05-10 | Foundation Medicine, Inc. | Composite immune biomarkers and uses thereof |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1991003489A1 (en) | 1989-09-08 | 1991-03-21 | The Johns Hopkins University | Structural alterations of the egf receptor gene in human gliomas |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
CA2129663C (en) | 1992-02-06 | 2005-07-05 | James S. Huston | Biosynthetic binding protein for cancer marker |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
DK0836605T3 (da) | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
EP0892789B2 (en) | 1996-04-12 | 2009-11-18 | Warner-Lambert Company LLC | Irreversible inhibitors of tyrosine kinases |
EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
HUP0104211A3 (en) | 1998-11-19 | 2003-01-28 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
ATE344801T1 (de) | 1999-12-29 | 2006-11-15 | Immunogen Inc | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
HU231090B1 (hu) | 2000-10-06 | 2020-07-28 | Kyowa Kirin Co., Ltd. | Antitest-kompozíciót termelő sejt |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
CA2838062C (en) | 2001-08-03 | 2015-12-22 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
WO2003084570A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia |
AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
SI1725249T1 (sl) | 2003-11-06 | 2014-04-30 | Seattle Genetics, Inc. | Spojine monometilvalina, sposobne konjugacije na ligande |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
AU2005230848B9 (en) | 2004-03-31 | 2011-06-02 | Genentech, Inc. | Humanized anti-TGF-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
ES2403055T3 (es) | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
WO2006034488A2 (en) | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
CN101213297B (zh) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
US8219149B2 (en) | 2005-06-29 | 2012-07-10 | Nokia Corporation | Mobile communication terminal |
KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
HUE034465T2 (en) | 2008-02-11 | 2018-02-28 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
CA2823621C (en) | 2010-12-30 | 2023-04-25 | Foundation Medicine, Inc. | Optimization of multigene analysis of tumor samples |
WO2012106175A1 (en) | 2011-02-02 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma |
CN104094266A (zh) | 2011-11-07 | 2014-10-08 | 独创系统公司 | 用于识别原因性基因组变体的方法和系统 |
US20140287937A1 (en) | 2013-02-21 | 2014-09-25 | Toma Biosciences, Inc. | Methods for assessing cancer |
EP4253558A1 (en) | 2013-03-15 | 2023-10-04 | The Board of Trustees of the Leland Stanford Junior University | Identification and use of circulating nucleic acid tumor markers |
KR20230070054A (ko) | 2013-03-15 | 2023-05-19 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
AU2014262481A1 (en) | 2013-05-10 | 2015-11-26 | Foundation Medicine, Inc. | Analysis of genetic variants |
EP3527587A1 (en) | 2013-12-17 | 2019-08-21 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists |
WO2015116868A2 (en) | 2014-01-29 | 2015-08-06 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
CA2946759A1 (en) | 2014-04-25 | 2015-10-29 | Memorial Sloan-Kettering Cancer Center | Treatment of h-ras-driven tumors |
US20160009805A1 (en) * | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
WO2016018481A2 (en) | 2014-07-28 | 2016-02-04 | The Regents Of The University Of California | Network based stratification of tumor mutations |
SG10201914022QA (en) | 2014-11-13 | 2020-03-30 | Univ Johns Hopkins | Checkpoint blockade and microsatellite instability |
MA40737A (fr) * | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
SG11201703925VA (en) * | 2014-12-02 | 2017-06-29 | Celgene Corp | Combination therapies |
US20180045727A1 (en) | 2015-03-03 | 2018-02-15 | Caris Mpi, Inc. | Molecular profiling for cancer |
HRP20201900T4 (hr) | 2015-05-12 | 2024-06-07 | F. Hoffmann - La Roche Ag | Terapeutski i dijagnostički postupci kod raka |
US20180231554A1 (en) | 2015-09-04 | 2018-08-16 | The Brigham And Women's Hospital, Inc. | Programmed cell death (pd-1) inhibitor therapy for patients with pd-1-expressing cancers |
MX2018010361A (es) | 2016-02-29 | 2019-07-08 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
CN109476731A (zh) | 2016-02-29 | 2019-03-15 | 基础医药有限公司 | 治疗癌症的方法 |
CN109196359B (zh) | 2016-02-29 | 2022-04-12 | 基础医疗股份有限公司 | 用于评估肿瘤突变负荷的方法和系统 |
EP3433373B1 (en) * | 2016-03-22 | 2022-01-12 | Myriad Women's Health, Inc. | Combinatorial dna screening |
AU2017339517B2 (en) | 2016-10-06 | 2024-03-14 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
CN110913901A (zh) * | 2017-03-31 | 2020-03-24 | 免疫医疗有限责任公司 | 通过无细胞dna测量肿瘤负荷 |
-
2018
- 2018-07-20 AU AU2018304458A patent/AU2018304458B2/en active Active
- 2018-07-20 JP JP2020502304A patent/JP2020527351A/ja active Pending
- 2018-07-20 KR KR1020237044463A patent/KR20240006698A/ko not_active Application Discontinuation
- 2018-07-20 KR KR1020207004659A patent/KR20200093518A/ko not_active IP Right Cessation
- 2018-07-20 CA CA3069469A patent/CA3069469A1/en active Pending
- 2018-07-20 CN CN201880060374.9A patent/CN111492245A/zh active Pending
- 2018-07-20 US US16/041,363 patent/US11674962B2/en active Active
- 2018-07-20 EP EP18750078.0A patent/EP3655034A1/en active Pending
- 2018-07-20 WO PCT/US2018/043074 patent/WO2019018757A1/en unknown
- 2018-07-20 MX MX2020000604A patent/MX2020000604A/es unknown
- 2018-07-20 TW TW107125127A patent/TWI823859B/zh active
- 2018-07-20 IL IL271888A patent/IL271888B1/en unknown
-
2022
- 2022-01-10 AU AU2022200109A patent/AU2022200109A1/en active Pending
-
2023
- 2023-04-20 JP JP2023069140A patent/JP2023103258A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022200109A1 (en) | 2022-02-03 |
CN111492245A (zh) | 2020-08-04 |
TW201908730A (zh) | 2019-03-01 |
IL271888A (en) | 2020-02-27 |
US20190025308A1 (en) | 2019-01-24 |
AU2018304458B2 (en) | 2021-12-09 |
US11674962B2 (en) | 2023-06-13 |
KR20240006698A (ko) | 2024-01-15 |
WO2019018757A1 (en) | 2019-01-24 |
EP3655034A1 (en) | 2020-05-27 |
KR20200093518A (ko) | 2020-08-05 |
JP2020527351A (ja) | 2020-09-10 |
CA3069469A1 (en) | 2019-01-24 |
AU2018304458A1 (en) | 2020-02-06 |
JP2023103258A (ja) | 2023-07-26 |
IL271888B1 (en) | 2024-05-01 |
TWI823859B (zh) | 2023-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020000604A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
MX2023002251A (es) | Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer. | |
MX2018010361A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
CY1122871T1 (el) | Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1 | |
EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
WO2020023420A3 (en) | Methods and systems for adjusting tumor mutational burden by tumor fraction and coverage | |
EA201792679A1 (ru) | Способы диагностики и лечения злокачественной опухоли | |
MX2018013744A (es) | Metodos para clasificar pacientes con un cancer solido. | |
NZ759958A (en) | Neoantigen identification, manufacture, and use | |
GB2552267A (en) | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results | |
AU2018329925A8 (en) | Diagnostic and therapeutic methods for cancer | |
WO2017214373A8 (en) | Diagnostic and therapeutic methods for cancer | |
MX2018008169A (es) | Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante. | |
MX2018006781A (es) | Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap. | |
WO2011133609A3 (en) | Methods and kits to predict therapeutic outcome of btk inhibitors | |
EA201992026A1 (ru) | Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5 | |
Wennemers et al. | Regulation of TRIB3 mRNA and protein in breast cancer | |
MX339340B (es) | Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico. | |
ZA202301267B (en) | S100 proteins as novel therapeutic targets in myeloproliferative neoplasms | |
MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
EP3640643A3 (en) | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker | |
Zhao et al. | Loss expression of micro ribonucleic acid (miRNA)‐200c induces adverse post‐surgical prognosis of advanced stage non‐small cell lung carcinoma and its potential relationship with ETAR messenger RNA | |
TW202428305A (zh) | 癌症之診斷及治療方法 | |
WO2015144184A8 (en) | Use of timp-1 as a biomarker in the egf-receptor inhibitor treatment of metastatic colorectal cancer |